Atom Investors LP Mersana Therapeutics, Inc. Transaction History

Atom Investors LP

$906 Million
Q3 2024

A detailed history of Atom Investors LP transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Atom Investors LP holds 24,661 shares of MRSN stock, worth $51,048. This represents 0.01% of its overall portfolio holdings.

Number of Shares

24,661

Previous 365,435 93.25%

Holding current value

$51,048

Previous $734,000 93.73%

% of portfolio

0.01%

Previous 0.08%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.23 - $2.25 $419,152 - $766,741	-340,774 Reduced 93.25%	24,661 $46,000
Q2 2024 Aug 14, 2024	SELL	$2.0 - $4.45 $147,594 - $328,396	-73,797 Reduced 16.8%	365,435 $734,000
Q1 2024 May 15, 2024	SELL	$2.16 - $5.94 $724,522 - $1.99 Million	-335,427 Reduced 43.3%	439,232 $1.97 Million
Q4 2023 Feb 14, 2024	BUY	$1.11 - $2.34 $534,445 - $1.13 Million	481,482 Added 164.23%	774,659 $1.8 Million
Q3 2023 Nov 14, 2023	BUY	$1.06 - $3.91 $310,767 - $1.15 Million	293,177 New	293,177 $372,000
Q3 2022 Nov 08, 2022	BUY	$4.63 - $8.0 $116,231 - $200,832	25,104 New	25,104 $170,000
Q1 2021 May 17, 2021	SELL	$15.31 - $26.52 $5.8 Million - $10.1 Million	-379,136 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$16.84 - $27.59 $396,245 - $649,192	23,530 Added 6.62%	379,136 $10.1 Million
Q3 2020 Nov 13, 2020	BUY	$16.2 - $25.7 $4.67 Million - $7.41 Million	288,467 Added 429.66%	355,606 $6.62 Million
Q2 2020 Aug 14, 2020	BUY	$5.24 - $23.4 $351,808 - $1.57 Million	67,139 New	67,139 $1.57 Million

Others Institutions Holding MRSN

# of Institutions

121

Shares Held

116M

Call Options Held

233K

Put Options Held

457K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $201M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Atom Investors LP, based on Form 13F filings with the SEC.

News

Stay updated on Atom Investors LP with notifications on news.

Account

Atom Investors LP Mersana Therapeutics, Inc. Transaction History